{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:13:27Z","timestamp":1774430007035,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019349","name":"Nanjing Medical Science and Technique Development Foundation","doi-asserted-by":"crossref","award":["YKK15068"],"award-info":[{"award-number":["YKK15068"]}],"id":[{"id":"10.13039\/501100019349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019349","name":"Nanjing Medical Science and Technique Development Foundation","doi-asserted-by":"crossref","award":["YKK17074"],"award-info":[{"award-number":["YKK17074"]}],"id":[{"id":"10.13039\/501100019349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>There is currently no optimal treatment modality for refractory or relapsed Extranodal NK\/T-cell lymphoma, nasal type (ENKTL). In recent years, programmed cell death protein 1 (PD-1)\/programmed cell \u2013 ligand 1 pathway blockade and histone deacetylase inhibitors have emerged as promising strategies for refractory or relapsed ENKTL. Accumulating evidence has shown that therapeutic effects of anti-PD-1 antibody could be enhanced by histone deacetylase inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient Concerns:<\/jats:title>\n            <jats:p>A 52-year-old male patient was diagnosed with stage I ENKTL by biopsy on February 2010.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>positron emission tomography\u2013computed tomography (PET-CT) and biopsy were used to diagnose relapsed ENKTL in 2014.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with radiotherapy and six cycles of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride and achieved complete remission (CR) by PET-CT in August 2010. In November 2014, the patient was diagnosed with relapsed stage IV ENKTL and was treated with six cycles of alternative chemotherapy with the regimen of steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide and pegaspargase plus Gemcitabine, Oxaliplatin along with radiotherapy. The patient achieved remission and was placed on thalidomide maintenance treatment. Upon suspicion of relapse suggested by PET-CT, Autologous stem cell transplant was performed after BCNU, etoposide, Ara-C, and melphalan preconditioning on February 2016. Following relapse again in December 2016, the lesions of left femur were treated with radiotherapy and he received anti-PD-1 antibody. He was treated with 4 cycles of pegaspargase plus Gemcitabine, Oxaliplatin on August 2017. The patient's condition improved. He received maintenance and consolidation therapy including lenalidomide, radiotherapy of the right nasal cavity and paranasal sinuses and antigen-specific reactive T cell infusions. PET-CT imaging showed there was high metabolic activity signal in the distal end of right femoral on August 2018 and the treatment regimen was adjusted to radiotherapy of the distal end of right femoral and systemic treatment of PD-1 antibody Sintilimab and chidamide 30\u200amg. After 5\u200amonths post-treatment, biopsy of nasopharynx showed no lymphoma cells. The patient continued the treatment of Sintilimab and chidamide 20\u200amg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>PET-CT imaging showed his lesions obtained remission after 8\u200amonths post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Thus, combination of sintilimab and chidamide can be used to treat relapsed ENKTL following treatment failure from chemo-, radio-, and immuno-therapy. A clinical trial has been launched.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024824","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:02:44Z","timestamp":1615510964000},"page":"e24824","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Sustained remission of multi-line relapsed extranodal NK\/T-cell lymphoma, nasal type, following sintilimab and chidamide"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4093-855X","authenticated-orcid":false,"given":"Jingyan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xihui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"R1-20250504","first-page":"111","article-title":"Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10 002 cases [J]","volume":"11","author":"Li","year":"2012","journal-title":"J Diagn Concepts Pract"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"8050","DOI":"10.1200\/JCO.2020.38.15_suppl.8050","article-title":"Sintilimab for relapsed\/refractory (r\/r) extranodal NK\/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4)","volume":"38","author":"Li","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/mt.2015.91","article-title":"Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol Ther"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00277-016-2818-4","article-title":"Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK\/T-cell lymphoma, nasal type","volume":"96","author":"Jo","year":"2017","journal-title":"Ann Hematol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immuno, Immunothera"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"33035","DOI":"10.18632\/oncotarget.8847","article-title":"High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK\/T cell lymphoma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/hon.2758","article-title":"Predicting treatment response of patients with extranodal natural killer\/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1 [J]","volume":"38","author":"Feng","year":"2020","journal-title":"Hematol Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fonc.2020.00699","article-title":"Inhibition of Histone Deacetylase (HDAC) enhances checkpoint blockade efficacy by rendering bladder cancer cells visible for T cell-mediated destruction","volume":"10","author":"Burke","year":"2020","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:03:39Z","timestamp":1746338619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024824"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024824","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2020-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}